| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1043763682 |
| P356 | DOI | 10.1186/S40880-016-0111-5 |
| P8608 | Fatcat ID | release_zw3tiuc7bje3jnujj77g3vsecu |
| P3181 | OpenCitations bibliographic resource ID | 1240103 |
| P932 | PMC publication ID | 4896142 |
| P698 | PubMed publication ID | 27233623 |
| P2093 | author name string | Tao Chen | |
| Ping-Hong Zhou | |||
| Xiao-Yue Xu | |||
| P2860 | cites work | Mutational landscape of gastric adenocarcinoma in Chinese: implications for prognosis and therapy | Q35038084 |
| Topoisomerase IIα in chromosome instability and personalized cancer therapy. | Q35498796 | ||
| Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer | Q35554809 | ||
| Microsatellite instability in gastrointestinal tract cancers: a brief update | Q36338134 | ||
| Meta-analysis shows that prevalence of Epstein-Barr virus-positive gastric cancer differs based on sex and anatomic location | Q36443305 | ||
| Molecular targeted therapy for advanced gastric cancer | Q36705689 | ||
| Targeted anti-mitotic therapies: can we improve on tubulin agents? | Q36717905 | ||
| The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection | Q36737159 | ||
| Acquired resistance to tyrosine kinase inhibitors during cancer therapy | Q37104243 | ||
| Polo on the Rise-from Mitotic Entry to Cytokinesis with Plk1. | Q37162736 | ||
| Epstein-Barr virus infection as an epigenetic driver of tumorigenesis | Q38023841 | ||
| Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial | Q38099726 | ||
| Molecular targeted agents for gastric cancer: a step forward towards personalized therapy. | Q38161727 | ||
| Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory | Q38192810 | ||
| Epstein-Barr virus and Burkitt lymphoma. | Q38270680 | ||
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial | Q38364028 | ||
| Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma | Q38527516 | ||
| Gene mutations in gastric cancer: a review of recent next-generation sequencing studies | Q38585708 | ||
| Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays | Q39455013 | ||
| Amplification and overexpression of Aurora-A in esophageal squamous cell carcinoma. | Q40153506 | ||
| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
| Amplification/overexpression of Aurora-A in human gastric carcinoma: potential role in differentiated type gastric carcinogenesis. | Q40529341 | ||
| Overexpression and amplification of Aurora-A in hepatocellular carcinoma | Q40574136 | ||
| Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. | Q41038524 | ||
| TCGA divides gastric cancer into four molecular subtypes: implications for individualized therapeutics | Q42946075 | ||
| Molecular profiling of gastric cancer: toward personalized cancer medicine | Q44309359 | ||
| A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer | Q44370429 | ||
| Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas | Q44867167 | ||
| Lymphoepithelial carcinoma of the stomach with Epstein-Barr virus demonstrated by polymerase chain reaction. | Q45851280 | ||
| Comparative analysis of protein expressions in primary and metastatic gastric carcinomas | Q46331500 | ||
| Targeting cell cycle kinases and kinesins in anticancer drug development. | Q52639097 | ||
| An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. | Q53308405 | ||
| Targeting polo-like kinase 1 for cancer therapy. | Q53348000 | ||
| The significance of unstable chromosomes in colorectal cancer. | Q53376250 | ||
| Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. | Q53381806 | ||
| The prevalence of PIK3CA mutations in gastric and colon cancer. | Q54655912 | ||
| Genomic alterations in primary gastric adenocarcinomas correlate with clinicopathological characteristics and survival. | Q55085529 | ||
| Epstein-Barr virus and nasopharyngeal carcinoma | Q56947843 | ||
| Gastric cancer | Q57758203 | ||
| Correlation of histologic subtypes and replication error phenotype with comparative genomic hybridization in gastric cancer | Q73271649 | ||
| 17q12-21 amplicon, a novel recurrent genetic change in intestinal type of gastric carcinoma: a comparative genomic hybridization study | Q73683259 | ||
| Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma | Q77557047 | ||
| Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer | Q83660023 | ||
| Global cancer statistics | Q22241238 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Treatment of gastric cancer | Q24602875 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Molecular classification and prediction in gastric cancer | Q26783806 | ||
| What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway | Q26825780 | ||
| Aurora kinase A in gastrointestinal cancers: time to target | Q26864277 | ||
| Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer | Q27851407 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study | Q27853010 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| From molecular classification to targeted therapeutics: the changing face of systemic therapy in metastatic gastroesophageal cancer | Q28082921 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers | Q28272347 | ||
| Polo-like kinases and the orchestration of cell division | Q29616759 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Q29617772 | ||
| Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Q29620051 | ||
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Q29620596 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Nivolumab in previously untreated melanoma without BRAF mutation | Q29620688 | ||
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 | ||
| PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 | ||
| Genome-wide analysis of DNA copy number alterations and gene expression in gastric cancer | Q33370136 | ||
| A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours | Q33398444 | ||
| A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. | Q33414793 | ||
| A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma | Q33944281 | ||
| VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA | Q33971399 | ||
| The incidences and mortalities of major cancers in China, 2010. | Q34055553 | ||
| Up-regulation of PIK3CA promotes metastasis in gastric carcinoma | Q34213783 | ||
| Cancer-specific mutations in PIK3CA are oncogenic in vivo | Q34335169 | ||
| Polo-like kinases and oncogenesis | Q34382988 | ||
| VEGF-targeted therapy: mechanisms of anti-tumour activity. | Q34791610 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | genetic variation | Q349856 |
| stomach neoplasm | Q4335552 | ||
| Epstein–Barr virus infection | Q5384031 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 49 | |
| P577 | publication date | 2016-05-27 | |
| P1433 | published in | Chinese Journal of Cancer | Q15760211 |
| P1476 | title | Emerging molecular classifications and therapeutic implications for gastric cancer | |
| P478 | volume | 35 |
| Q49202365 | A gene expression-based risk model reveals prognosis of gastric cancer |
| Q100955017 | Classification of gastric cancers based on immunogenomic profiling |
| Q38646259 | Clinicopathological and prognostic characteristics in patients with AFP-secreting gastric carcinoma |
| Q28073757 | Gastric cancer: current and evolving treatment landscape |
| Q48026879 | Identification of a prognostic 5-Gene expression signature for gastric cancer |
| Q64123203 | Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer |
| Q60949479 | Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer |
| Q33696201 | Molecular classifications of gastric cancers: Novel insights and possible future applications |
| Q42200325 | Nomogram analysis and external validation to predict the risk of lymph node metastasis in gastric cancer |
| Q90164263 | Optimization of perioperative approaches for advanced and late stages of gastric cancer: clinical proposal based on literature evidence, personal experience, and ongoing trials and research |
| Q39170872 | Predictive biomarkers along gastric cancer pathogenetic pathways |
| Q57167306 | Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer |
| Q55603677 | Proposed Molecular and miRNA Classification of Gastric Cancer. |
| Q90333943 | Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers |
| Q42399338 | The journey of personalizing gastric cancer treatment |
Search more.